Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MaxCyte Inc (MXCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: MXCT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.68
1 Year Target Price $6.68
| 6 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.49% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 160.98M USD | Price to earnings Ratio - | 1Y Target Price 6.68 |
Price to earnings Ratio - | 1Y Target Price 6.68 | ||
Volume (30-day avg) 6 | Beta 0.27 | 52 Weeks Range 1.26 - 5.20 | Updated Date 10/30/2025 |
52 Weeks Range 1.26 - 5.20 | Updated Date 10/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.1 | Actual - |
Profitability
Profit Margin -125.22% | Operating Margin (TTM) -167.24% |
Management Effectiveness
Return on Assets (TTM) -14.19% | Return on Equity (TTM) -21.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 63581703 | Price to Sales(TTM) 4.5 |
Enterprise Value 63581703 | Price to Sales(TTM) 4.5 | ||
Enterprise Value to Revenue 1.78 | Enterprise Value to EBITDA -11.07 | Shares Outstanding 106606648 | Shares Floating 96184782 |
Shares Outstanding 106606648 | Shares Floating 96184782 | ||
Percent Insiders 1.77 | Percent Institutions 77.42 |
Upturn AI SWOT
MaxCyte Inc
Company Overview
History and Background
MaxCyte, Inc. was founded in 1998. It focuses on cell engineering and developing solutions for drug discovery, biomanufacturing, and cell therapy. Initially, the company focused on developing its Flow Electroporation technology. Over time, it expanded its offerings to include cell engineering platforms and partnered with biotech and pharmaceutical companies to advance cell-based therapies.
Core Business Areas
- ExPERT Platform: The ExPERT platform is MaxCyte's core technology, enabling complex cell engineering for therapeutic development and manufacturing. It enables delivery of a wide range of molecules into cells, supporting gene editing, cell modification, and protein production.
- CARMA Platform: The CARMA platform enables the engineering of CAR T-cells. This enables the development of enhanced cell therapies.
- Bioprocessing: MaxCyte supports biomanufacturing via cell engineering. This involves enabling efficient and scalable production of cell-based products.
Leadership and Structure
MaxCyte is led by a management team with experience in cell therapy, biomanufacturing, and commercialization. The company has a board of directors responsible for oversight and strategic direction.
Top Products and Market Share
Key Offerings
- ExPERT Platform: MaxCyte's ExPERT platform drives much of the companyu2019s revenue. The ExPERT platform enables stable and transient cell engineering without the limitations associated with viral vectors. The competitors for this product are Lonza (LONN.SW) and Thermo Fisher Scientific (TMO).
Market Dynamics
Industry Overview
The cell therapy and biomanufacturing industries are experiencing rapid growth driven by advancements in gene editing, personalized medicine, and bioprocessing technologies. The demand for efficient cell engineering solutions is increasing. MaxCyte's platform sits at the intersection of cell therapy and biomanufacturing. The cell therapy sector has grown tremendously due to advancements in CAR-T cell technology.
Positioning
MaxCyte is positioned as a cell engineering company. The company's competitive advantage lies in its electroporation technology, which enables efficient delivery of molecules into cells with minimal cytotoxicity. This is used to make cell therapy production more efficient.
Total Addressable Market (TAM)
The cell therapy market is expected to reach USD 76.0 billion by 2030. MaxCyte is positioned to capture a portion of this market through its cell engineering technology, though there's not a clear breakout to the percentage of market share specifically addressed by cell engineering alone within the therapy market.
Upturn SWOT Analysis
Strengths
- Proprietary electroporation technology
- Strong partnerships with leading biotech and pharmaceutical companies
- Scalable manufacturing platform
- Expertise in cell engineering
Weaknesses
- Dependence on partnerships for revenue
- Relatively small company compared to competitors
- High operating expenses
- Lack of profitability
Opportunities
- Expanding applications of cell therapy
- Increasing demand for biomanufacturing solutions
- Potential for new partnerships
- Technological advancement in cell engineering
Threats
- Competition from established bioprocessing companies
- Regulatory hurdles for cell therapy products
- Technological disruptions
- Economic downturns
Competitors and Market Share
Key Competitors
- Lonza (LONN.SW)
- Thermo Fisher Scientific (TMO)
- Miltenyi Biotec (No US Stock Symbol)
Competitive Landscape
MaxCyte has a competitive advantage in its electroporation technology. However, Lonza and Thermo Fisher Scientific have larger resources and broader product offerings.
Growth Trajectory and Initiatives
Historical Growth: MaxCyte has demonstrated historical growth in revenue, driven by new partnerships and platform adoption.
Future Projections: Analyst estimates project continued revenue growth but a gradual path to profitability.
Recent Initiatives: Recent strategic initiatives include new partnerships, platform enhancements, and expansion into new therapeutic areas.
Summary
MaxCyte is a developing biotechnology company with a promising cell engineering platform. While it is not currently profitable and relies on partnerships for revenue, the growth in cell therapy presents a good opportunity for the company. MaxCyte should focus on continuing to expand its partnership agreements, and improve its cost structure and profitability. The relatively small company is at risk from competitors and economic downturns.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Financial Reports
- Analyst Reports
- Industry Publications
- Company Investor Relations
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance may change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MaxCyte Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2021-07-30 | President, CEO & Executive Director Mr. Maher Masoud | ||
Sector Healthcare | Industry Medical Devices | Full time employees 114 | Website https://www.maxcyte.com |
Full time employees 114 | Website https://www.maxcyte.com | ||
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.